Abstract
Intravesical therapy with bacillus Calmette-Guérin has proven effects for reducing recurrence, progression, and death from non-muscle-invasive bladder cancer. These advantages are seen mainly when appropriate maintenance therapy is used for 1-3 years, in the context of appropriate patient selection, tumor management, and symptom support for potential side effects.